Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 19 November, 2024
Author: Getaka|Social: Getaka Financial Services X (Earlier Twitter) Profile Getaka Financial Services LinkedIn Logo
Stock Ticker - BSE: 524348 | NSE: AARTIDRUGS

Aarti Drugs Limited: Intrinsic Value and Fundamental Analysis

Share Price and Basic Stock Data

Last Updated: November 19, 2024, 7:32 pm

Market Cap 4,226 Cr.
Current Price 460
High / Low635/430
Stock P/E33.8
Book Value 126
Dividend Yield0.22 %
ROCE13.7 %
ROE12.4 %
Face Value 10.0
PEG Ratio-2.67

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Aarti Drugs Limited

Competitors of Aarti Drugs Limited

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Gujarat Themis Biosyn Ltd 3,574 Cr. 328390/10867.8 20.50.20 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 61.0 Cr. 82.294.9/25.823.4 11.90.00 %9.72 %3.44 % 10.0
Gujarat Inject (Kerala) Ltd 28.0 Cr. 19.119.5/8.3536.3 6.640.00 %4.06 %3.33 % 10.0
Godavari Drugs Ltd 86.3 Cr. 115155/87.012.9 55.40.00 %12.7 %15.5 % 10.0
Glenmark Life Sciences Ltd 13,185 Cr. 1,0771,335/62031.1 2072.09 %28.1 %21.1 % 2.00
Industry Average15,044.04N/A43.90N/AN/A16.2516.45N/A

All Competitor Stocks of Aarti Drugs Limited

Quarterly Result

MonthJun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
Sales506511593641551625626696592578538560493
Expenses432442503557496555557608520512478490439
Operating Profit74699184557069897265606954
OPM %15%14%15%13%10%11%11%13%12%11%11%12%11%
Other Income2121001111210
Interest4556789888787
Depreciation12121212121212121212121212
Profit before tax60537567365049695347435035
Tax %24%24%26%21%28%27%25%23%25%26%26%27%23%
Net Profit46415653263737534035323627
EPS in Rs4.924.396.035.722.853.953.965.744.273.763.443.932.93

Last Updated: Unknown

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: September 20, 2024, 5:26 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
Sales8269721,0871,0761,0891,1401,4541,6351,9152,2512,4982,2672,168
Expenses7038229159009109551,2521,3871,5111,9302,2121,9981,920
Operating Profit123150172176179185203248404321286269248
OPM %15%15%16%16%16%16%14%15%21%14%11%12%11%
Other Income-0110416975244
Interest31374247383641362623363330
Depreciation26283136373840474847474848
Profit before tax668610093108112128175338256205192175
Tax %31%28%22%29%30%35%32%22%24%24%25%26%
Net Profit45627866757387136258195153142129
EPS in Rs4.676.388.016.847.917.789.2514.5627.6521.0616.5015.4314.06
Dividend Payout %27%26%41%25%3%3%3%3%9%5%6%6%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)37.78%25.81%-15.38%13.64%-2.67%19.18%56.32%89.71%-24.42%-21.54%-7.19%
Change in YoY Net Profit Growth (%)0.00%-11.97%-41.19%29.02%-16.30%21.84%37.14%33.38%-114.12%2.88%14.35%

Aarti Drugs Limited has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:9%
5 Years:9%
3 Years:6%
TTM:-14%
Compounded Profit Growth
10 Years:9%
5 Years:11%
3 Years:-18%
TTM:-24%
Stock Price CAGR
10 Years:16%
5 Years:29%
3 Years:-5%
1 Year:-3%
Return on Equity
10 Years:20%
5 Years:20%
3 Years:16%
Last Year:12%

Last Updated: Unknown

Balance Sheet

Last Updated: November 15, 2024, 1:47 am

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital12122424242424239393939291
Reserves1962392793263634104955987668801,0221,0831,068
Borrowings296342435465448517471378336519535475499
Other Liabilities216257228240281366384471442543546522463
Total Liabilities7208509671,0551,1161,3161,3731,4711,6372,0352,1962,1722,122
Fixed Assets291373431463542564586612631649634722747
CWIP1381334142832111660161222243
Investments551111181719202428293030
Other Assets4114645115475417077368289661,2971,3721,1981,102
Total Assets7208509671,0551,1161,3161,3731,4711,6372,0352,1962,1722,122

Reserves and Borrowings Chart

Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +72951071251746214719615440162337
Cash from Investing Activity +-58-105-102-87-96-71-59-29-69-125-131-187
Cash from Financing Activity +-1611-5-37-789-87-168-8584-31-149
Net Cash Flow-22-11-0-01-1-0-101

Free Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow-173.00-192.00-263.00-289.00-269.00-332.00-268.00-130.0068.00-198.00-249.00-206.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days951041031099311711010496115117104
Inventory Days9571778710113286107125120102107
Days Payable888475859112586110941038996
Cash Conversion Cycle10191105110103124109101127133130115
Working Capital Days101909710810312810895118132128117
ROCE %20%22%21%18%17%17%17%20%33%21%15%14%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
Promoters59.99%59.83%59.98%59.77%59.66%59.57%58.70%58.57%57.47%57.13%55.67%55.64%
FIIs2.03%2.07%2.07%1.94%1.90%1.94%1.97%2.33%2.10%2.56%2.95%2.50%
DIIs2.28%2.69%2.76%3.16%3.90%4.09%4.72%5.32%5.26%5.99%7.35%7.83%
Public35.71%35.41%35.19%35.11%34.53%34.39%34.63%33.78%35.16%34.30%34.01%34.01%
No. of Shareholders1,95,4691,89,6071,86,6741,80,3031,73,2831,69,0901,62,4091,67,4461,70,4141,57,5471,50,2181,90,281

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
DSP Small Cap Fund4,636,3771.63270.214602024-11-161007808.04%
DSP Healthcare Fund737,6711.4742.994602024-11-16160263.26%
Motilal Oswal BSE Healthcare ETF4600.150.034602024-11-160%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue10.0010.0010.0010.0010.00
Basic EPS (Rs.)18.5617.9722.1230.0960.57
Diluted EPS (Rs.)18.5617.9722.1230.0960.57
Cash EPS (Rs.)24.2623.4027.5435.4481.61
Book Value[Excl.RevalReserv]/Share (Rs.)139.43128.80111.9198.00280.04
Book Value[Incl.RevalReserv]/Share (Rs.)139.43128.80111.9198.00280.04
Revenue From Operations / Share (Rs.)275.02293.31268.75231.20775.14
PBDIT / Share (Rs.)34.8633.2436.8047.38113.00
PBIT / Share (Rs.)29.2627.8131.3942.0392.08
PBT / Share (Rs.)25.6224.2129.1539.5979.52
Net Profit / Share (Rs.)18.6617.9722.1430.0960.69
NP After MI And SOA / Share (Rs.)18.6617.9622.1430.0960.69
PBDIT Margin (%)12.6711.3313.6920.4914.57
PBIT Margin (%)10.649.4711.6818.1811.87
PBT Margin (%)9.318.2510.8417.1210.25
Net Profit Margin (%)6.786.128.2313.017.82
NP After MI And SOA Margin (%)6.786.128.2313.017.82
Return on Networth / Equity (%)13.3813.9419.7830.6921.67
Return on Capital Employeed (%)16.4317.2922.9233.4622.54
Return On Assets (%)7.056.869.2815.878.96
Long Term Debt / Equity (X)0.210.170.130.160.27
Total Debt / Equity (X)0.430.500.510.330.51
Asset Turnover Ratio (%)1.041.171.181.191.12
Current Ratio (X)1.661.601.481.771.45
Quick Ratio (X)1.051.050.921.080.92
Inventory Turnover Ratio (X)3.143.393.373.153.89
Dividend Payout Ratio (NP) (%)0.005.564.518.304.94
Dividend Payout Ratio (CP) (%)0.004.273.637.053.67
Earning Retention Ratio (%)0.0094.4495.4991.7095.06
Cash Earning Retention Ratio (%)0.0095.7396.3792.9596.33
Interest Coverage Ratio (X)9.569.2516.4219.247.81
Interest Coverage Ratio (Post Tax) (X)6.126.0010.8813.205.06
Enterprise Value (Cr.)4542.223725.824488.496770.511508.91
EV / Net Operating Revenue (X)1.801.371.803.140.83
EV / EBITDA (X)14.1712.1013.1715.335.73
MarketCap / Net Operating Revenue (X)1.581.151.603.010.65
Retention Ratios (%)0.0094.4395.4891.6995.05
Price / BV (X)3.112.623.837.091.81
Price / Net Operating Revenue (X)1.581.151.603.010.65
EarningsYield0.040.050.050.040.11

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Aarti Drugs Limited as of November 19, 2024 is: 529.25

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of November 19, 2024, Aarti Drugs Limited is Undervalued by 15.05% compared to the current share price 460.00

Intrinsic Value of Aarti Drugs Limited as of November 19, 2024 is: 462.29

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of November 19, 2024, Aarti Drugs Limited is Undervalued by 0.50% compared to the current share price 460.00

Last 5 Year EPS CAGR: -12.65%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 19.58%, which is a positive sign.
  2. The company has higher reserves (594.23 cr) compared to borrowings (439.69 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (139.46 cr) and profit (156.46 cr) over the years.
  1. The stock has a high average Working Capital Days of 110.42, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 112.42, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Aarti Drugs Limited:
    1. Net Profit Margin: 6.78%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 16.43% (Industry Average ROCE: 16.25%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 13.38% (Industry Average ROE: 16.45%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 6.12
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.05
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 33.8 (Industry average Stock P/E: 43.9)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.43
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Aarti Drugs Ltd. is a Public Limited Listed company incorporated on 28/09/1984 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L37060MH1984PLC055433 and registration number is 055433. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 2251.17 Cr. and Equity Capital is Rs. 92.60 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
PharmaceuticalsPlot No. 198, M.I.D.C., Palghar District Maharashtra 401506investorrelations@aartidrugs.com
http://www.aartidrugs.co.in
Management
NamePosition Held
Mr. Chandrakant V GogriChairman Emeritus
Mr. Prakash M PatilChairman & M.D & CEO
Mr. Rashesh C GogriManaging Director
Mr. Harshit M SavlaJoint Managing Director
Mr. Harit P ShahExecutive Director
Mr. Uday M PatilExecutive Director
Mr. Narendra J SalviNon Executive Director
Mr. Ankit V PalejaIndependent Director
Prof. Bhaskar N ThoratIndependent Director
Mrs. Neha R GadaIndependent Director
Mr. Hasmukh B DedhiaIndependent Director
Mr. Sandeep M JoshiIndependent Director
Mr. Ajit E VenugopalanIndependent Director

FAQ

What is the latest intrinsic value of Aarti Drugs Limited?

The latest intrinsic value of Aarti Drugs Limited as on 19 November 2024 is ₹529.25, which is 15.05% higher than the current market price of ₹460.00.

What is the Market Cap of Aarti Drugs Limited?

The Market Cap of Aarti Drugs Limited is 4,226 Cr..

What is the current Stock Price of Aarti Drugs Limited as on 19 November 2024?

The current stock price of Aarti Drugs Limited as on 19 November 2024 is ₹460.

What is the High / Low of Aarti Drugs Limited stocks in FY 2024?

In FY 2024, the High / Low of Aarti Drugs Limited stocks is 635/430.

What is the Stock P/E of Aarti Drugs Limited?

The Stock P/E of Aarti Drugs Limited is 33.8.

What is the Book Value of Aarti Drugs Limited?

The Book Value of Aarti Drugs Limited is 126.

What is the Dividend Yield of Aarti Drugs Limited?

The Dividend Yield of Aarti Drugs Limited is 0.22 %.

What is the ROCE of Aarti Drugs Limited?

The ROCE of Aarti Drugs Limited is 13.7 %.

What is the ROE of Aarti Drugs Limited?

The ROE of Aarti Drugs Limited is 12.4 %.

What is the Face Value of Aarti Drugs Limited?

The Face Value of Aarti Drugs Limited is 10.0.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Aarti Drugs Limited. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE